# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate...
In the second half of 2024, SpringWorks also plans to file a Marketing Authorization Application (MAA) with the European Medici...
- SEC Filing
- SEC Filing
- SEC Filing
- SEC Filing
HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...
HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...
HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...